VivoSeq
Neurology

Status Epilepticus

35

Pipeline Programs↗

11

Active Trials↗

15

Companies Involved↗

Status Epilepticus is a moderately active landscape with 35 programs across 15 companies. The most active players are Marinus Pharmaceuticals, Supernus Pharmaceuticals, Inc., AstraZeneca. 5 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

19/100

Mech. Concentration

38/100

Completion Rate

76/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Marinus Pharmaceuticals

1 program

Phase 2Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2C

Catalyst Biosciences

1 program

Phase 2Takeda logo

Takeda

2 programs

Phase 3I

Immedica Pharma AB

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

41 of 42 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.

Analysis

Trial Status

57

clinical trials

Completed28 · 49%
Unknown status8 · 14%
Recruiting8 · 14%
Withdrawn5 · 9%
Terminated4 · 7%
Not yet recruiting2 · 4%
Other2 · 4%

Clinical Trials

Trial Activity

57 trials

Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest
Recruiting·UUniversity of Milano Bicocca·N/A·NCT05756621·80 enrolled
Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children
Recruiting·SSohag University·Phase 2/3·NCT07046611·124 enrolled
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)
Recruiting·SSohag University·Phase 2/3·NCT07095842·668 enrolled
Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)
Recruiting·UUniversity of Southern Denmark·Phase 3·NCT05263674·140 enrolled
A Survey of Midazolam in People With Status Epilepticus
Recruiting·—·N/A·NCT05313308·50 enrolled
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
Recruiting·UUniversity of California, San Francisco·Phase 2·NCT05851391·30 enrolled
Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)
Recruiting·UUniversity of Virginia·Phase 3·NCT06907173·770 enrolled
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
Recruiting·UUniversity of California, San Francisco·Phase 2·NCT06401707·52 enrolled
Ketamine for the Treatment of Refractory Status Epilepticus
Not yet recruiting·TThomas Jefferson University·Phase 4·NCT07177235·50 enrolled
Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus
Not yet recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·N/A·NCT06966830·100 enrolled
The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus
Enrolling by invitation·—·Phase 4·NCT06403150·62 enrolled
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
Completed·MMarinus Pharmaceuticals·Phase 2·NCT03350035·17 enrolled
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
Completed·Takeda logoTakeda·Phase 3·NCT03336645·25 enrolled
Established Status Epilepticus Treatment Trial
Completed·UUniversity of Virginia·Phase 3·NCT01960075·478 enrolled
Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus
Completed·—·Phase 2·NCT02920060·80 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)